INZY Inozyme Pharma, Inc.

5d ago, source: Seeking Alpha

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

1mon ago, source: Business Insider

For more information, please visit https://gaciglobal.org. Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of ...

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18d ago, source: Business Insider

AboutInozymePharma Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, ...

Inozyme Pharma Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inozyme Pharma Stock (NASDAQ:INZY), Analyst Ratings, Price Targets, Predictions

1mon ago, source: Benzinga.com

$7.06 183.29% HC Wainwright & Co.

Inozyme Pharma stock target cut, maintains Buy rating

15d ago, source: Investing

On Tuesday, H.C. Wainwright adjusted its price target for Inozyme Pharma Inc. (NASDAQ:INZY), reducing it to $14 from the previous $16, while continuing to endorse a Buy rating for the stock.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

16d ago, source: ADVFN

INZY Inozyme Pharma Inc Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency ...

Inozyme Pharma, Inc. (INZY)

7d ago, source: Yahoo Finance

- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study ...

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

1mon ago, source: Nasdaq

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton.

Inozyme Pharma Inc Ordinary Shares

20d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inozyme Pharma, Inc. (INZY)

1mon ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Inozyme Pharma Inc.

27d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...